GuidelineJAMA2021
Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement.
Guideline in JAMA, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 983 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mobile 3D C-arm CT for Lung Tumor Localization Efficacy Analysis: a Prospective Clinical Trial
Assessment of a Novel Blood Test in Early Detection of the Five Common Cancers Based on the Investigation of the Circulating Tumour DNA
Taiwan Real-world Low-dose Computed Tomography Screening behavIor and Outcome Research for High Risk Subjects Based on Health Promotion Administration-part A: Questionnaire Survey -Part B: LDCT Screening Outcome and Management
Investigating Incidental Pulmonary Nodules in Underserved Communities
Understanding Lung Cancer Related Risk Factors and Their Impact
Multi-center Prospective Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer
CHAMP: Community Health Assessment and Monitoring in the Pharmacy. Assessing the Impact of a Community Pharmacist Lung Cancer Screening (LCS) Program
Who cites it
983 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,627 citations in OpenAlex.
- AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation.Hepatology (Baltimore, Md.) · 2026Guideline
- ESR Essentials: lung cancer screening with low-dose CT-practice recommendations by the European Society of Thoracic Imaging.European radiology · 2026Guideline
- Use and impact of risk-based eligibility models in low-dose computed tomography lung cancer screening: a systematic review.Public health reviews · 2026Pooled it
- Health Communication and Stepped Reminders Interventions for Lung Cancer Screening: A Randomized Clinical Trial.JAMA internal medicine · 2026Trial
- Real-time AR navigation with dynamic tracking for millimeter-level pulmonary nodule localization: A randomized clinical trial.Cell reports. Medicine · 2026Trial
- Significant Incidental Findings in the National Lung Screening Trial and Diagnosis of Extrapulmonary Cancer.JAMA network open · 2026Trial
- Enhancement of Patient-Centered Lung Cancer Screening: The MyLungHealth Randomized Clinical Trial.JAMA oncology · 2026Trial
- Trial
- Potential to improve early detection of lung cancer through expansion of focused and opportunistic screening approaches: a scoping review focusing on potential expansion of screening risk factors and adoption of artificial intelligence models.Lung cancer management · 2026Review
- Long-term efficacy and adherence of a lung cancer screening strategy with extended LDCT intervals: Results from the BioMILD trial.Lung cancer (Amsterdam, Netherlands) · 2026Article
- Pulmonary nodules: classification, biomarkers, signaling pathways, diseases, early diagnosis and management.Signal transduction and targeted therapy · 2026Review
- Beyond Screening Populations: Context-Dependent Performance of Lung Cancer Risk Assessment Strategies in a Diagnostically Enriched Cohort.Healthcare (Basel, Switzerland) · 2026Article
- Two-Phase Occupational Screening in Coal-Fired Power Plant Workers: Anamnestic Risk Stratification and Targeted Low-Dose CT Findings.Diagnostics (Basel, Switzerland) · 2026Article
- Exhaled Breath Analysis for Lung Cancer Detection: From VOCs Signatures to EBC-Based Liquid Biopsy and Clinical Translation.Thoracic cancer · 2026Review
- Large-scale esophageal cancer screening through noncontrast computed tomography and artificial intelligence.Nature medicine · 2026Article
- Allostatic load, genetic susceptibility, and lung cancer risk: Evidence from a prospective cohort and integrative proteomic analyses.PLOS digital health · 2026Article
- [Implementation of a national lung cancer screening in Austria : Position paper of the Austrian Radiological Society (ÖRG), the Austrian Society of Pneumology (ÖGP), the Austrian Society of General Practice and Family Medicine (ÖGAM) and the Austrian Society of Thoracic Surgery (ÖGTC)].Wiener klinische Wochenschrift · 2026Article
- Associations between Metabolomic Signatures of Persistent Smoking Effects and Lung Cancer Risk among Former Smokers.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Robotic-Assisted Bronchoscopy for Peripheral Pulmonary Lesions: Current Evidence, Clinical Applications, and Future Directions.Diagnostics (Basel, Switzerland) · 2026Review
- Informing the cultural adaptation of a lung cancer screening shared decision-making and navigation intervention for Hispanic adults: a qualitative study.Cancer causes & control : CCC · 2026Article
923 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- SummaryForPatientsIn
Authors and funding
20 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceLung cancer is the second most common cancer and the leading cause of cancer death in the US. In 2020, an estimated 228 820 persons were diagnosed with lung cancer, and 135 720 persons died of the disease. The most important risk factor for lung cancer is smoking. Increasing age is also a risk factor for lung cancer. Lung cancer has a generally poor prognosis, with an overall 5-year survival rate of 20.5%. However, early-stage lung cancer has a better prognosis and is more amenable to treatment.
objectiveTo update its 2013 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the accuracy of screening for lung cancer with low-dose computed tomography (LDCT) and on the benefits and harms of screening for lung cancer and commissioned a collaborative modeling study to provide information about the optimum age at which to begin and end screening, the optimal screening interval, and the relative benefits and harms of different screening strategies compared with modified versions of multivariate risk prediction models. POPULATION: This recommendation statement applies to adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. EVIDENCE ASSESSMENT: The USPSTF concludes with moderate certainty that annual screening for lung cancer with LDCT has a moderate net benefit in persons at high risk of lung cancer based on age, total cumulative exposure to tobacco smoke, and years since quitting smoking. RECOMMENDATION: The USPSTF recommends annual screening for lung cancer with LDCT in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. (B recommendation) This recommendation replaces the 2013 USPSTF statement that recommended annual screening for lung cancer with LDCT in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.